Top 10 Small Cap Stocks With Huge Growth Potential

8. AtriCure, Inc. (NASDAQ:ATRC)

Stock Upside: 67.76%

Market Capitalization: $1.45 billion

Number of Hedge Fund Holders: 27

AtriCure, Inc. (NASDAQ:ATRC) is one of the top small cap stocks with huge growth potential. On May 6, Needham reiterated its Buy rating and $45 price target on AtriCure, Inc. (NASDAQ:ATRC) after the company delivered blowout Q1 2026 earnings.

AtriCure shared the earnings on May 5 and reported quarterly worldwide revenue of $141.2 million, a 14.3% jump year over year. This figure exceeded the analyst consensus estimate by about 1.4%. Mike Carrel, President and CEO, explained on the earnings call that this beat was made possible by a 28% growth in the pain management segment. This growth came on the back of the cryoSPHERE MAX probe. Other drivers the CEO pointed to are growth in the appendage management segment and open ablation.

Needham acknowledged the performance but noted that the key highlight that caught their attention was the accelerated timeline on the BoxX-NoAF clinical trial. This is a study testing a minimally invasive procedure to treat atrial fibrillation. AtriCure now expects patient enrollment to be complete by the end of this year, which is a whole 12 months ahead of its prior plan. This also means the trial results could be available in 2027 instead of 2028. For Needham, this is a major development because a positive data readout could unlock a major new market opportunity for AtriCure.

AtriCure, Inc. (NASDAQ:ATRC) is a medical device company. It develops technologies for the treatment of atrial fibrillation and related cardiac conditions. Its products include ablation systems, surgical devices, and appendage management technologies used by cardiac surgeons and electrophysiologists worldwide.